Clinical Trials Browser

Interventional × entrectinib × CNS × Clear all

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03994796 2026-03-04

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2 Suspended

186 enrolled

CNS

Brain Neoplasms, Neoplasm Metastasis

NCT06528691 2026-02-17

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

52 enrolled

CNS

Glioma, Central Nervous System Neoplasms

NCT02650401 2025-12-24

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

Clinical Trials

STARTRK-2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

STARTRK-NG